Annexon Inc. (ANNX)
1.46
0.03 (2.10%)
At close: Apr 17, 2025, 3:59 PM
1.46
-0.21%
After-hours: Apr 17, 2025, 07:58 PM EDT
2.10% (1D)
| Bid | 1.4 |
| Market Cap | 160.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -138.2M |
| EPS (ttm) | -1.01 |
| PE Ratio (ttm) | -1.45 |
| Forward PE | -1.09 |
| Analyst | Buy |
| Ask | 1.51 |
| Volume | 831,744 |
| Avg. Volume (20D) | 1,599,277 |
| Open | 1.43 |
| Previous Close | 1.43 |
| Day's Range | 1.41 - 1.47 |
| 52-Week Range | 1.28 - 7.85 |
| Beta | 1.24 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/II...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 100
Stock Exchange NASDAQ
Ticker Symbol ANNX
Website https://www.annexonbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ANNX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 995.89% from the latest price.
Stock Forecasts1 week ago
-5.52%
Annexon shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago
+13.96%
Annexon shares are trading higher after the company announced topline results from a study supporting Anx005 as a potential treatment for Guillain-barré syndrome.
